


**ASX: ALA**

Arovella Therapeutics Limited  
ACN 090 987 250



## **ASX Release**

17 November 2022

### **AROVELLA TO PRESENT AT BIOTECH SHOWCASE™ 2023**

**MELBOURNE, AUSTRALIA 17 November 2022:** Arovella Therapeutics, (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is pleased to announce that its CEO and Managing Director Dr Michael Baker will present at the annual Biotech Showcase™ event, being held 9-11 January 2023 in San Francisco.

Dr Baker will present the Arovella Therapeutics story to attendees of the event, focusing on the Company's iNKT cell therapy platform and its use for the treatment of blood cancers and solid tumours.

Biotech Showcase™ is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of the JP Morgan Healthcare Conference, one of the biotech sector's largest gatherings and busiest weeks, held concurrently in San Francisco.

Further details on the event are available at: <https://informaconnect.com/biotech-showcase/>

*Release authorised by the Managing Director and Chief Executive Officer of Arovella Therapeutics Limited.*

**Dr Michael Baker**

**Chief Executive Officer & Managing Director**

**Arovella Therapeutics Ltd**

Tel +61 (0) 403 468 187

[mbaker@arovella.com](mailto:mbaker@arovella.com)

## **NOTES TO EDITORS:**

### **About Arovella Therapeutics Ltd**

Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing therapies to treat human diseases. Arovella is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arovella is also expanding its DKK1-peptide targeting technology licenced from MD Anderson and used in conjunction with its iNKT cell therapy platform. The Company is also commercialising ZolpiMist™, a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. ZolpiMist is approved by the FDA and the TGA and is marketed in the USA. Arovella has rights to the product outside of the US and Canada.

For more information, visit [www.arovella.com](http://www.arovella.com)

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties

**ASX: ALA**

Arovella Therapeutics Limited  
ACN 090 987 250



and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding actions of third parties and financial terms. These factors and assumptions are based upon currently available information and the forward-looking statements contained herein speak only as of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include, but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.